AD/PD 2023 | Detecting retinal Aβ: a promising path for non-invasive Alzheimer’s disease diagnosis

Mourad Tayebi, PhD, Western Sydney University in Penrith, Australia, discusses his work towards the development of an ‘eye test’ for Alzheimer’s disease (AD), using nanobodies targeted towards retinal amyloid-beta (Aβ) oligomers. The team have developed nanobodies fused to near-infrared fluorescent proteins that are able to discriminate between APP/PS1 mice and control mice with high sensitivity and specificity. Looking ahead, Dr Tayebi is collaborating with a company to develop a miniature, portable OCT device able to easily detect the presence of retinal Aβ. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.